Clinical markers associated with glycaemic response to dipeptidyl peptidase-4 inhibitor therapy

被引：2
|
作者：
Yamagishi, Sho-ichi [1 ]
机构：
[1] Kurume Univ, Sch Med, Dept Pathophysiol & Therapeut Diabet Vasc Complic, Kurume, Fukuoka 8300011, Japan
来源：
DIABETES-METABOLISM RESEARCH AND REVIEWS | 2018年 / 34卷 / 07期
关键词：
advanced glycation end products; DPP-4; insulin resistance; oxidative stress; GLYCATION END-PRODUCTS; DPP-4; OBESITY; GLP-1;
D O I：
10.1002/dmrr.3024
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Clinical Utility of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin
    Grunberger, George
    POSTGRADUATE MEDICINE, 2013, 125 (03) : 79 - 90
  • [2] Dipeptidyl peptidase-4 inhibitor approaches
    Bloomgarden, Zachary
    JOURNAL OF DIABETES, 2017, 9 (01) : 5 - 7
  • [3] Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor
    Boulton, David W.
    CLINICAL PHARMACOKINETICS, 2017, 56 (01) : 11 - 24
  • [4] Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor
    Kano, Yasuhiro
    Kato, Miyuki
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (34) : E1186 - E1187
  • [5] Collagenous Colitis Possibly Associated with Dipeptidyl Peptidase-4 Inhibitor
    Takedomi, Hironobu
    Sakata, Yasuhisa
    Tomonaga, Michito
    Naruse, Naomi
    Yukimoto, Takahiro
    Akutagawa, Takashi
    Tsuruoka, Nanae
    Shimoda, Ryo
    Kido, Shinichi
    Esaki, Motohiro
    INTERNAL MEDICINE, 2022, 61 (18) : 2731 - 2734
  • [6] Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor
    Kano, Yasuhiro
    Kato, Miyuki
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (20) : E705 - E705
  • [7] Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition
    Kirby, Mark
    Yu, Denise M. T.
    O'Connor, Stephen P.
    Gorrell, Mark D.
    CLINICAL SCIENCE, 2010, 118 (1-2) : 31 - 41
  • [8] Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor
    David W. Boulton
    Clinical Pharmacokinetics, 2017, 56 : 11 - 24
  • [9] Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
    Tasanen, Kaisa
    Varpuluoma, Outi
    Nishie, Wataru
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [10] Localized bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor treatment
    Oya, Kazumasa
    Fujii, Masanao
    Taguchi, Shijima
    Nishie, Wataru
    Izumi, Kentaro
    Shimizu, Hiroshi
    EUROPEAN JOURNAL OF DERMATOLOGY, 2018, 28 (02) : 250 - 251
12345